Episealer® presentations at several clinical congresses
Episurf Medical (Nasdaq: EPIS B) today announces that the company’s knee and ankle technologies, Episealer® Knee and Talus, recently have been presented at several clinical congresses, as part of the scientific program or through surgeon-led initiatives.
At the 29th International Congress of SLAOT (Sociedad Latinoamericana de Ortopedia y Traumatología) in San José, Costa Rica (September 20-22), Dr Christian Kothny gave a presentation on the Episealer® implant technologies, focusing on clinical indications, surgical techniques, and clinical results. At the XL Orthopedic Days, organised by the Polish Society of Orthopaedics and Traumatology (Poznań, Poland, September 22-23), Prof. Łukasz Łapaj gave a presentation where similar topics were covered. At the 17th World Congress of ICRS (International Cartilage Regeneration & Joint Preservation Society, Barcelona, Spain, September 9-12), the Episealer® implant systems were included in presentations by Dr Francesca de Caro and Priv.-Doz. Dr. med. Philip Rößler.
“We are pleased to see that surgeons globally are directing their attention to the Episealer® technology at an increasing pace. Our initially targeted patient population has always been an important discussion topic at clinical congresses, given the treatment challenges. Our results show that surgeons have an expanded toolbox to treat these patients. Combined with the efficient surgical technique and pre-surgical planning, the Episealer® represents an attractive option for surgeons, and we believe that the technology is starting to receive the attention it deserves”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 09:45 CEST on 25 September 2023.
Tags: